NuPathe to Present at Upcoming Investor Conferences

Date : 02/07/2012 @ 9:05PM
Source : Marketwired
Stock : Nupathe Inc. (MM) (PATH)
Quote : 4.25  0.0 (0.00%) @ 12:00AM

NuPathe to Present at Upcoming Investor Conferences

Nupathe Inc. (MM) (NASDAQ:PATH)
Historical Stock Chart

5 Years : From Feb 2015 to Feb 2020

Click Here for more Nupathe Inc. (MM) Charts.

NuPathe Inc. (NASDAQ: PATH), an emerging biopharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, today announced that Jane Hollingsworth, chief executive officer, will present company overviews at two upcoming investor conferences.

On Tuesday, February 14, 2012, NuPathe will present at the 14th Annual BIO CEO & Investor Conference at 3:00 p.m. EST. The conference is being held at The Waldorf Astoria Hotel in New York, NY.

On Wednesday, February 15, 2012, NuPathe will present at the Leerink Swann 2012 Global Healthcare Conference at 4:00 p.m. EST. The conference is also being held at The Waldorf Astoria Hotel in New York, NY.

Live audio webcasts of the presentations will be available via the "Investor Relations" page of the NuPathe website, www.nupathe.com. Please log on through NuPathe's website approximately 10 minutes prior to the scheduled start time. Replays of the webcasts will also be archived on NuPathe's website for 90 days following the presentation.

About NuPathe NuPathe Inc. (www.nupathe.com) is an emerging biopharmaceutical company focused on innovative neuroscience solutions for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe's lead product candidate, NP101, is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to NP101, NuPathe has two additional proprietary product candidates in preclinical development: NP201 for the continuous symptomatic treatment of Parkinson's disease, which the company plans to partner, and NP202 for the long-term treatment of schizophrenia and bipolar disorder.

Contact Information: John Woolford Westwicke Partners, LLC (443) 213-0506 john.woolford@westwicke.com Keith A. Goldan Vice President & Chief Financial Officer NuPathe Inc. (484) 567-0130

Latest PATH Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.